Agenda Introduction Classes of recommendations Level of evidence

Slides:



Advertisements
Similar presentations
Linoxsmart S DX Master Study
Advertisements

Prevalence and Predictors of Off-label Use of Cardiac Resynchronization Therapy: A Report from the ICD Registry TM Adam S. Fein * MD, Yongfei Wang ¥ MS,
Presenter Disclosure Information
Long Distance Titration of Heart Failure Medications by Telephone Calls Anne E. Steckler, RN, Heba Wassif, MD, Kalkidan Bishu, MD, Gardar Sigurdsson, MD,
EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.
Advanced Heart Failure and the Role of Mechanical Circulatory Support
RAte Control Efficacy in Permanent Atrial Fibrillation A Randomized Comparison of Lenient Rate Control versus Strict Rate Control Concerning Morbidity.
Cardiac Insufficiency Bisoprolol Study (CIBIS III) Trial
Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices: Primary Results of the Registry to Improve Heart Failure Therapies.
MANAGING CONGESTIVE HEART FAILURE
Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
25 seconds left…...
1 ESC/EAS 2011 Guidelines for the management of dyslipidemias
Natale MARRAZZO Francesco SOLIMENE Quando la CRT-P può bastare?
The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis.
Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.
analysis from the SHIFT study
SOLVD (Studies of Left Ventricular Dysfunction)
Heart Failure: Living with a Hurting Heart. Congestive Heart Failure Heart (or cardiac) failure is the state in which the heart is unable to pump blood.
Prepared by : Nehad J. Ahmed.  Heart failure, also known as congestive heart failure (CHF), means your heart can't pump enough blood to meet your body's.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes Guy Amit, MD; Mahmoud Suleiman, MD; Mark Kazatsker,
Heartland Cardiology Dr. John Dongas The Beat Goes On: Biventricular Devices.
May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
ACC Heart Failure Guidelines Slide Deck Based on the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult.
JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults p.o.box zip code Done by: Dr.Amin Zagzoog.
Treatment of Heart Failure: Beyond Medical Therapy
Current Management of Heart Failure GP clinical update 17 th June 2015 Dr Raj Bilku Consultant Cardiologist Clinical Lead Cardiology QEH.
Heart Failure Management Applying the ACC/AHA Chronic Heart Failure Guidelines David Bragin Sánchez MD FACC Cardiomyopathy and Cardiac Transplant Specialist.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:
To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE DISEASE MANAGEMENT STANDARDS.
HEART FAILURE TEAM MEMBERSHIP
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
CIBIS II Cardiac Insufficiency Bisoprolol Study
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
An ICD for every CRT patient ?
Internal Medicine Workshop Series Laos September /October 2009
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.
RCTs in Cardiac Resynchronization Therapy StudyPtNYHALVEFLVEDDRhythmQRSICD PATH-CHF41III,IV≤35%AnySR≥120N MUSTIC58III≤35%≥60SR≥150N MIRACLE453III,IV≤35%≥55SR≥130N.
HEART FAILURE TEAM MEMBERSHIP DEPARTMENTS OF CARDIOLOGY, CARDIOVASCULAR SURGERY, MEDICINE, NURSING, QUALITY AND RESOURCE MANAGEMENT, THE CENTER FOR CLINICAL.
To know more visit HeartFailure.com © 2016 Novartis Pharma AG, July 2016, GLCM/HTF/0028c HEART FAILURE DISEASE MANAGEMENT STANDARDS.
Fig ACCF/AHA Guideline for the management of heart failure
Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;
Ivabradine – A new option for Heart Failure Patients
Heart Failure Management
Optimal Pacing for Right Ventricular and Biventricular Devices
Cardiovacular Research Technologies
The American Heart Association
Diabetes Mellitus and Heart Failure
Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection  Derek V. Exner, MD, MPH, David.
Clyde W. Yancy et al. JACC 2017;70:
Erratum Heart Rhythm Volume 8, Issue 4, (April 2011)
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.
ACC Heart Failure Guidelines Slide Deck
Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.
Presentation transcript:

ESC Guidelines Heart failure update 2008 ESC Guidelines Update 2008 For internal training purpose. European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC guidelines in 2008 Recommendations for device in patients with LV systolic dysfunction Treatment overview in CHF BIOTRONIKs CRT/ICD products

In the new ESC CHF guidelines there are four revised recommendations related to CRM device therapy. CRT-D recommended as routine therapy in heart failure patients to reduce mortality and morbidity Class I – Level of evidence A (previously Level of evidence B) -NYHA III-IV class -OPT, LVEF≤35% -QRS≥120 ms CRT-P Class IIb Level C (previously in NYHA III-IV) -Concomitant indication for permanent pacing in NYHA II-IV -LVEF≤35% or LV dilatation DDD-pacemakers Class IIb Level C (first time recommended) -Heart failure and sinus rhythm Remote monitoring Class IIa Level of evidence C (first time recommended) European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

Treatment algorithm for patients with symptomatic heart failure & reduced ejection fraction Heart Failure (with symptoms) & reduced EF Diuretic ACE-Is1 ARBs2 Titrate -Blocker ADD3 OPT 1 Angiotension-converting enzyme inhibitors 2 Angiotensin receptor blockers 3 Aldosterone antagonists 4 Left ventricular assist device Persisting signs and symptoms? Yes No QRS > 120ms? LVEF<35%? Yes No Yes No Consider: CRT-P or CRT-D Consider: digoxin, hydralazine/ nitrate, LVAD4, transplantation Consider: ICD No further treatment indicated European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC guidelines in 2008 Recommendations for device in patients with LV systolic dysfunction Treatment overview in CHF BIOTRONIKs CRT/ICD products

Classes of recommendations Evidence and/or general agreement that a given treatment or procedure is beneficial, and effective. Is recommended/ is indicated Class I Class II Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure. Weight of evidence/opinion is in favour of usefulness/efficacy.  Should be considered. II A Usefulness/efficacy is less established by evidence/opinion.  May be considered. II B Class III Evidence or general agreement that the given treatment or procedure is not useful/effective and in some cases may be harmful.  Is not recommended. European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC guidelines in 2008 Recommendations for device in patients with LV systolic dysfunction Treatment overview in CHF BIOTRONIKs CRT/ICD products

Level of evidence Level of evidence A Data derived from multiple randomized clinical trials or meta-analyses. Level of evidence B Data derived from a single randomized clinical trial or large non-randomized studies. Level of evidence C Consensus of opinion of experts and/or small studies, retrospective studies, and registries. European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC guidelines in 2008 Recommendations for device in patients with LV systolic dysfunction Treatment overview in CHF BIOTRONIKs CRT/ICD products

Treatment algorithm for patients with symptomatic heart failure & reduced ejection fraction Heart Failure (with symptoms) & reduced EF Diuretic ACE-Is1 ARBs2 Titrate -Blocker ADD3 OPT 1 Angiotension-converting enzyme inhibitors 2 Angiotensin receptor blockers 3 Aldosterone antagonists 4 Left ventricular assist device Persisting signs and symptoms? Yes No QRS > 120ms? LVEF<35%? Yes No Yes No Consider: CRT-P or CRT-D Consider: digoxin, hydralazine/ nitrate, LVAD4, transplantation Consider: ICD No further treatment indicated European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC guidelines in 2008 Recommendations for device in patients with LV systolic dysfunction Treatment overview in CHF BIOTRONIKs CRT/ICD products

CRT-P and CRT-D(new) Guidelines recommend Class I Level of evidence A Now CRT-D is also recommended as Class I Level of evidence A. Patient population NYHA class III/IV, OPT, LVEF ≤35%, QRS≥120 ms Improve symptoms/reduce hospitalization Reduce mortality Clinical benefit Clinical trial evidence CRT-D indications have been changed according to the results of COMPANION. COMPANION1 demonstrated a significant decrease in total mortality in CRT-D patients. 1 Bristow MR et al.; N Engl J Med 2004;350:2140–2150. European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

Remote monitoring Guidelines recommend Class IIb Level of evidence C Based on the Wilkoff et al. consensus paper remote monitoring has been recommended for the first time. “Remote monitoring is the continuous collection of patient information and to review this information without patient present. …remote monitoring may decrease healthcare utilization through fewer hospital admissions for chronic HF, fewer heart failure-related re-admissions, and more efficient device management. Ongoing trials will assess the clinical utility of such an approach.” Based on the consensus paper: (Wilkoff B. et al.; HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Heart Rhythm. 2008; 5(6):907-25.) European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

Pacemakers Guidelines recommend Class IIa Level of evidence C. CRT-P recommendation addresses new patient population in NYHA II. Patients with concomitant indication for permanent pacing (first implant or upgrading of a conventional pacemaker) in NYHA II-IV, LVEF≤35%, or LV dilatation. CRT-P devices Patient population Clinical benefit Avoid deleterious or increase dyssynchrony due to right ventricular pacing. Patient population Clinical benefit Maintain normal chronotropic response and coordinate the atrial and ventricular contraction. DDD-pacemakers Patients with heart failure and sinus rhythm. European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC guidelines in 2008 Recommendations for device in patients with LV systolic dysfunction Treatment overview in CHF BIOTRONIKs CRT/ICD products

CRT-P and CRT-D Guidelines recommend Class I Level of evidence A. Patient population NYHA III-IV class with symptoms OPT, LVEF≤35% QRS≥120 ms Improve symptoms /reduce hospitalizations Reduce morbidity and mortality Clinical benefit European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

ICD 1/3 Guidelines recommend Class I Level of evidence A. Patient population Secondary prevention (survivor of ventricular fibrillation, patients with documented haemodynamically unstable VT and/or VT with syncope) OPT, LVEF≤40% Survival expectation > 1year Reduce mortality Clinical benefit European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

ICD 2/3 Guidelines recommend Class I Level of evidence A. Patient population Primary prevention in NYHA II/III OPT, LVEF≤35% LV dysfunction due to MI >40 days Survival expectation > 1year Reduce mortality Clinical benefit European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

ICD 2/3 Guidelines recommend Class I Level of evidence B. Patient population Primary prevention in NYHA II/III OPT, LVEF≤35% Non-ischemic cardiomyopathy Survival expectation > 1year Reduce mortality Clinical benefit European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC guidelines in 2008 Recommendations for device in patients with LV systolic dysfunction Treatment overview in CHF BIOTRONIKs CRT/ICD products

Treatment overview in heart failure patients (1/2) NYHA I NYHA II NYHA III NYHA IV ACE-Is1 I A -Blockers I A ARBs2 I A AAD3 I B Angiotension-converting enzyme inhibitors Angiotensin receptor blockers Aldosterone antagonists ICD Secondary prevention Primary prevention ischemic post MI>40 days non-ischemic I A I A I B CRT (QRS>120ms) I A European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

Treatment overview in heart failure patients (2/2) Drug/Device Class/Evidence Clinical benefit Improves ventricular function and patient well-being Reduces hospital admission for worsening HF Increases survival ACE-I I A -Blockers I A ARBs I A AADs I B ICD Secondary prevention Primary prevention -ischemic post MI>40 d -non-ischemic I A Reduces mortality I A I B Improves symptoms/reduces hospitalizations Reduces mortality CRT I A European Heart Journal, doi: 10.1093/eurheart/ehn309 European Journal of Heart Failure doi: 10.1016/j.ejheart.2008.08.005

Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC guidelines in 2008 Recommendations for device in patients with LV systolic dysfunction Treatment overview in CHF BIOTRONIKs CRT/ICD products

BIOTRONIK provides a complete ICD/CRT product portfolio according to the ESC guidelines Therapy requirements BIOTRONIK devices Indication ICD indication Primary prevention ICD therapy and extended longevity VR-ICD Lumax 340 VR-T XL Lumax 540 VR-T VR-ICD Lexos Lumos Lumax 300/340 VR-T/XL Lumax 540 VR-T ICD indication Permanent AF ICD therapy and pacing in V ICD indication Pacing indication ICD therapy and pacing in A&V DR-ICD Lexos Lumos Lumax 300/340 DR-T Lumax 540 DR-T ICD indication Paroxymal AF, SVT ICD therapy and SVT discrimination CRT-D Lumax HF-T 300/340 ™ Lumax HF-T 540™ CRT-P Stratos NYHA III-IV class OPT, LVEF≤35% QRS≥120 ms Cardiac Resynchronization Therapy

Conclusion Guidelines now recommend CRT-D and CRT-P as routine heart failure therapy with Class I Level of evidence A. Remote monitoring of patients with CRM devices is recommended for the first time in the ESC guidelines. BIOTRONIK Home Monitoring®, TRUST and REFORM trials will provide further clinical evidence of the benefits of remote monitoring. New option of Stratos therapy, CRT-P, in NYHA II patients. BIOTRONIK ICD/CRT devices provide the advanced technology to fulfil guidelines recommendations.